TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Treatment with oral anti-diabetic drugs for at least 3 months~* HbA1c: 7.5-10.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy.~* Body Mass Index (BMI) less than or equal to 45 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last 3 months~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Steroid for Knee Arthroplasty Patients Expected to Have Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 40 and 90.~* Booked for unilateral knee-arthroplasty.~* Is able to take part in the investigation(selfreported pain and nausea/vomiting)~* Understands Danish or English, or has a translator available.~* Signed written consent.~* A daily use of 30 mg or more of morphine or morphine equivalents .~* A pain catastrophizing scale(PCS) score of \>20.~Exclusion Criteria:~* Insulin-dependent diabetes melitus.~* Ongoing treatment with systemic glucocorticoids or immunosuppressing treatment(apart from inhaled glucocorticoids).~* Pregnancy/Breastfeeding~* Allergies for the investigational drug.~* A history of schizophrenia or bipolar diseases, or patients with permanent use of antipsychotic medication.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- High dose Dexamethasone (Type: EXPERIMENTAL): An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
- Medium dose Dexamethasone (Type: ACTIVE_COMPARATOR): An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Aevidum Curriculum and Club

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Students (in grades 9-12; this is typically ages 14-18 years though a broader span was provided above) and staff from participating schools.~Exclusion Criteria:~* Students not enrolled in one of the participating high schools (n=12)~* Students not in grades 9-12~* Students with disabilities that are deemed unable to participate by the school district~* Non-English speaking students as curriculum and club materials are taught/available in English only at this time

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Aevidum curriculum (Type: ACTIVE_COMPARATOR): Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
- Aevidum curriculum + club (Type: ACTIVE_COMPARATOR): Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, healthy postmenopausal women with~  * Natural menopause and more than 5 years after their last menstrual period~ * or surgical menopause and more than 5 years after surgery~ * osteopenia (lumbar spine T score between 1 and 2.5 SD below the mean value in normal young women).~* With at least one risk factor for osteoporosis~Exclusion Criteria:~* Women who have received hormone replacement therapy (with estrogen and/or progestogen and/or androgen) or raloxifene within 3 months before visit 2 or calcitonin or calcitriol within 4 weeks before visit 2

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia27.~* Participants were required to get weight gain more than 10% of their predrug body weight during less than 12 months of treatment with a targeted antipsychotic agent- clozapine, olanzapine, risperidone or sulpiride.~* The duration of illness for all participants was less than 12 months.~* Participants could be taking only one antipsychotic, whose dose had not changed by changed by more than 25% over the past 3 months.~* All patients were stable outpatient.~* The total score of Positive and Negative Syndrome Scale (PANSS) for all patients could be ≤60.~* All participants were ensured that they could be carefully taken care of by one of their parents or guardians during the trial.~Exclusion Criteria:~* Participants were excluded from the study if they had evidence of liver or renal diseases, pregnant or lactating women, cardiovascular diseases, hypertension or diabetes mellitus, specific systemic diseases, or conditions that limited their ability to perform the lifestyle modifications, such as arthritis, pulmonary diseases, neurological or dietary restrictions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Müllerian carcinomas (primary epithelial ovarian, primary peritoneal, or fallopian tube) who have had a response to platinum-based chemotherapy and have a chemotherapy treatment-free interval of at least 6 months. These patients are designated potentially platinum-sensitive.~2. Measurable disease by radiological or clinical examination parameters.~3. No prior immunotherapy.~4. No concurrent steroids or radiation therapy.~5. Adequate hematological parameters (ANC \>/= 1500 cells/UL, platelets \>/= 100,000 cells/UL~6. Adequate renal function (serum creatinine \</= 1.5 mg/dl)~7. Adequate hepatic function (serum bilirubin \</= 1.5 mg/dl)~8. SGOT or SGPT \</= 2.5 normal~9. Zubrod status \</= 2~10. Signed informed consent~11. Patients with no more than 2 prior therapy regimens (1st line platinum and platinum reinduction will count as one)~Exclusion Criteria:~1. Pregnant or lactating women~2. Patients with brain metastases~3. Serum albumin \<3 gm/dl~4. Weight loss \>10% over 4 months~5. Radiation therapy to whole abdomen~6. History of clinical or EKG findings suggestive of active (within the last 6 months) heart disease~7. Patients with active autoimmune or inflammatory bowel disease~8. Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.~9. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.~10. Patients with prior hypersensitivity to platinum agents~11. Patients with history of other malignancy, with the exception of non-melanomatous skin cancer; unless in complete remission and off therapy for a minimum of 5 years.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemoimmunotherapy (Type: EXPERIMENTAL): GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marinol in Trichotillomania or Obsessive Compulsive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years~2. Obsessive-compulsive disorder (OCD), Trichotillomania (TTM), or Pathological Skin Picking (PSP) as the primary psychiatric diagnosis~3. (If OCD) - Subject reports ≥two failed treatments using selective serotonin reuptake inhibitors (SSRIs) for their OCD~4. Women's participation required negative results on a beta-human chorionic gonadotropin pregnancy test and stable use of a medically accepted form of contraception.~5. Signed informed consent before entry into the study.~Exclusion Criteria:~1. Unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screening visit~2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential~3. A need for medication other than dronabinol with possible psychotropic effects~4. History of hypersensitivity to any cannabinoid or sesame oil~5. Lifetime history of bipolar disorder type I or II, dementia, or schizophrenia as determined by the Structured Clinical Interview for DSM-IV~6. Current (past 12-months) DSM-IV substance abuse or dependence~7. Positive urine drug screen at screening~8. Initiation of cognitive behavior therapy within 3 months prior to study baseline~9. Baseline score of ≥ 17 on the Hamilton Depression Rating Scale (17-item HDRS~10. Suicidality based on clinical interview~11. History of head injury or neurological disorder (such as seizures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dronabinol (Type: EXPERIMENTAL): Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~- Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) at the screening visit.~OR~- Participants with primary hypercholesterolemia who were receiving a lipid-lowering treatment other than atorvastatin, or who were not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening if they were likely to have LDL-C ≥100 mg/dL (≥2.59 mmol/L) after a 6-week run-in treatment period on atorvastatin therapy.~Exclusion criteria:~1. LDL-C \<100 mg/dL (\<2.59 mmol/L)~   * at screening visit for participants who were being treated with stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening OR~  * at the end of the 6-week run-in period on atorvastatin for participants receiving a lipid lowering treatment other than atorvastatin, or not at stable dose of atorvastatin 5-20 mg for at least 6 weeks prior to screening~2. Participants with type 1 diabetes~3. Participants with type 2 diabetes treated with insulin, or without, and considered poorly controlled at screening.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 50 mg Q2W (Type: EXPERIMENTAL): Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 75 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 150 mg Q2W (Type: PLACEBO_COMPARATOR): Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of The Effect Of Propolis And Gluma Desensitizer On The Management Of Dentin Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18- 60 years.~* Patients who have at least one tooth of dentin hypersensitivity on right and left side of the mouth, non carious cervical lesion.~* Patients exhibiting pain scores of at least two on visual analogue scale would be included in the study~Exclusion Criteria:~* Teeth with fractures or cracks in the cervical areas of the teeth.~* Cervical areas that are involved in extensive fillings, dentures or orthodontics appliances.~* Patients who have a history of any psychological diseases.~* Patients who use analgesic/anti-inflammatory medicines on daily basis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- propolis (Type: EXPERIMENTAL): propolis will be applied to the affected teeth
- gluma desensitizer (Type: ACTIVE_COMPARATOR): Gluma desensitizer will be applied to the affected teeth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age more than or equal to 65 years based on the precise date of birth~* Discharge from hospital after hospitalization for a medical cause. All medical causes make patients eligible for enrolment with the only exception of medical causes mentioned in the exclusion criteria~Exclusion Criteria:~* Failure to obtain written informed consent~* Solid organ malignancy or lymphoma diagnosed the last five years~* Treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months~* Severely immunocompromised patients. This exclusion category comprises: a) patients with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic patients with less than 500 neutrophils/mm3; c) patients with solid organ transplantation; d) patients with bone marrow transplantation; e) patients under chemotherapy; f) patients with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies~* Positive Interferon-gamma Release Assay (IGRA)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One intradermal injection of 0.1ml of sodium chloride 0.9%
- Vaccination (Type: ACTIVE_COMPARATOR): One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female aged 18 to 75 years old, both inclusive.~* Patient has had a diagnosis of rheumatoid arthritis according to the 2010 American College of Rheumatology(ACR)/EULAR classification criteria for at least 24 weeks prior to the first administration of the study drug .~Exclusion Criteria:~* Patient who has previously received investigational or licensed product; biologic or targeted synthetic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis and/or a tumor necrosis factor (TNF) α inhibitor for any purposes.~* Patient who has allergies to any of the excipients of study drug or any other murine and human proteins, or patient with a hypersensitivity to immunoglobulin products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P17 Subcutaneous(SC) (adalimumab) (Type: EXPERIMENTAL): CT-P17 SC (adalimumab)
- Humira SC (adalimumab) (Type: ACTIVE_COMPARATOR): Humira SC (adalimumab)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Allergic/Non-Asthmatic subjects and Allergic/Asthmatic subjects~Inclusion Criteria:~* Positive skin test to dust mite or cat allergen~Non-Allergic/Non-Asthmatic subjects~Inclusion Criteria:~* Negative skin test to panel of 12 allergens, including dust mite and cat allergen~All groups~Exclusion Criteria:~* History of intubation for asthma exacerbation~* Use of Xolair (omalizumab) within the last 6 months~* Immunotherapy with cat or dust mite extract now or in the past 5 years~* ≥ 10 pack-years smoking or any smoking in the past year~* Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection~* History of dermatographia~* History of anaphylaxis to cat allergen~* Participation in another research study involving a drug or biologic during the past 30 days~* Presence of past or current medical problems/other factors that may pose additional risks from participation or influence study results, as determined per study investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Allergen challenge subjects (Type: EXPERIMENTAL): Intervention: Segmental airway allergen challenge~Three types of subjects are studied in this arm:~1) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Elective abdominal and orthopedic surgery~* A patent arterial line~* A patent IV line~* Must be able to read and speak English~Exclusion Criteria:~* Subjects unable to give informed consent.~* Allergy to cefazolin~* Cognitively Impared~* Prisoners~* Pregnant females (self reported)~* History of coagulopathy~* Subjects presenting for emergency abdominal surgery~* Creatinine clearance \< 30 ml/min~* Received cefazolin within 72 hours prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOLUS INFUSION (Type: ACTIVE_COMPARATOR): Bolus infusion of antibiotics
- CONTINUOUS INFUSION (Type: EXPERIMENTAL): Continuous infusion of antibiotics by way of infusion pump

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete